Trubion was a publicly held
biopharmaceutical
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...
company that was focused on creating a pipeline of protein-based therapeutic product candidates to treat
autoimmune
In immunology, autoimmunity is the system of immune responses of an organism against its own healthy cells, tissues and other normal body constituents. Any disease resulting from this type of immune response is termed an "autoimmune disease". ...
and
inflammatory diseases
Inflammation (from la, inflammatio) is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecu ...
and
cancer
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...
. Trubion was acquired by
Emergent BioSolutions
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides m ...
on October 28, 2010. Trubion was established in 1999 in the
State of Washington as an early stage development company, and was later reincorporated in October 2002 in the State of Delaware.
In December 2005, Trubion entered into a collaborative agreement with Wyeth
for the development and worldwide commercialization of CD20-directed therapeutics. The agreement also included the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion's contract with Wyeth extended through December 22, 2009.
Former product pipeline
Former technology
Trubion's product development efforts were focused on three technology pillars: SMIP protein therapeutics, SCORPION protein therapeutics, and TRU-ADhanCe potency enhancing technology for immunopharmaceuticals.
SMIP, or small modular immunopharmaceutical, therapeutics are single chain polypeptides comprising one binding domain, one hinge domain and one effector domain designed in an effort to meet predetermined therapeutic specifications for specific diseases. SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity). Trubion worked on SMIP drug candidates that targeted validated antigens with the same specificity and predictable biological activity as mAbs.
SCORPION protein therapeutics are also single chain polypeptides composed of functional domains from naturally occurring proteins. The difference between SMIP and SCORPION technologies is that SCORPION compounds are multi-specific therapeutics that are capable of targeting two or more antigens simultaneously.
TRU-ADhanCe potency enhancing technology was designed to enhance the potency of existing therapies that work through Fc-directed or antibody-directed cellular cytotoxicity, or Antibody-dependent cell-mediated cytotoxicity, ADCC. TRU-ADhanCe technology could be applied late in development to established manufacturing lines and generate candidates with increased ADCC and longer in vivo half lives.
References
{{Pharmaceutical companies of the United States
Biotechnology companies of the United States
Defunct pharmaceutical companies of the United States
Defunct companies based in Seattle
Companies formerly listed on the Nasdaq
Biotechnology companies established in 1999
Biotechnology companies disestablished in 2010
Pharmaceutical companies established in 1999
Pharmaceutical companies disestablished in 2010
1999 establishments in Washington (state)
2010 disestablishments in Washington (state)
2010 mergers and acquisitions